Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end...
Covered in this story
Analyst targets on Enliven Therapeutics Inc
- Guggenheim: $40.6 → $78 by Oct 2027 · Buy via Investing.com
- Morgan Stanley: $47 → $70 by Oct 2027 · Overweight via Investing.com
- JPMorgan: $46.2 → $75 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ELVN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Enliven Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.